Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis

被引:61
作者
Davies, R. J. [1 ]
Sangle, S. R. [1 ]
Jordan, N. P. [1 ]
Aslam, L. [1 ]
Lewis, M. J. [1 ]
Wedgwood, R. [1 ]
D'Cruz, D. P. [1 ]
机构
[1] St Thomas Hosp, Lupus Res Unit, Rayne Inst, London SE1 7EH, England
关键词
Systemic lupus erythematosus; lupus nephritis; B cell depletion; B-CELL DEPLETION; TERM-FOLLOW-UP; IMMUNOSUPPRESSIVE THERAPY; ERYTHEMATOSUS; TRIAL; EFFICACY; CYCLOPHOSPHAMIDE; CLASSIFICATION; SAFETY; INDEX;
D O I
10.1177/0961203313483376
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The objective of this paper is to report the clinical outcome of B cell depletion therapy in 18 patients with refractory lupus nephritis (LN). Methods: Eighteen patients received rituximab on an open-label basis with prospective evaluations. All patients had renal disease refractory to conventional immunosuppressive therapy, including intravenous cyclophosphamide (CyC). All patients fulfilled the revised ACR classification criteria for SLE. Rituximab was given as 2 x 1 g infusions with 500 mg iv CyC and 500 mg iv methylprednisolone, two weeks apart. Complete remission (CR) of nephritis at six months was defined as normal serum creatinine and serum albumin levels, inactive urine sediment, and protein-uria <0.5 g/day; partial remission (PR) was defined as a >= 50% improvement in all renal parameters that were abnormal at baseline. Clinical response was assessed by the British Isles Lupus Assessment Group (BILAG) score pre- and post-rituximab treatment, and efficacy was recorded by extent and duration of B lymphocyte depletion (normal range 0.100-0.500 x 10(9)/l). Follow-up data were collected at six months, one year post-treatment and at the most recent clinic visit. Results: At six months, 11/18 patients reached renal CR and two of 18 PR. The mean global BILAG scores for responders decreased from 15 (SD 10) to 5 (SD 3), and a total of ten A scores disappeared. Five patients failed to show complete or partial renal response despite peripheral B lymphocyte count depletion, and progressed to end-stage renal failure (ESRF) and dialysis. Four of these patients had severe proliferative, crescentic nephritis, of whom three had Class IV-G, one Class III and one late membranous glomerulonephritis. One patient died six years after rituximab therapy from overwhelming sepsis while on long-term haemodialysis. Conclusion: Rituximab therapy achieved a response in 13/18 patients with refractory LN. However, in patients with rapidly progressive crescentic LN, when there is already evidence of significant renal impairment, rituximab therapy may not prevent progression to ESRF and dialysis. Our data also suggest that severe Class IV-G LN may be associated with a poor response to therapy.
引用
收藏
页码:574 / 582
页数:9
相关论文
共 25 条
[1]   PROGNOSTIC FACTORS IN LUPUS NEPHRITIS - CONTRIBUTION OF RENAL HISTOLOGIC DATA [J].
AUSTIN, HA ;
MUENZ, LR ;
JOYCE, KM ;
ANTONOVYCH, TA ;
KULLICK, ME ;
KLIPPEL, JH ;
DECKER, JL ;
BALOW, JE .
AMERICAN JOURNAL OF MEDICINE, 1983, 75 (03) :382-391
[2]   CONTROLLED TRIAL OF PULSE METHYLPREDNISOLONE VERSUS 2 REGIMENS OF PULSE CYCLOPHOSPHAMIDE IN SEVERE LUPUS NEPHRITIS [J].
BOUMPAS, DT ;
AUSTIN, HA ;
VAUGHN, EM ;
KLIPPEL, JH ;
STEINBERG, AD ;
YARBORO, CH ;
BALOW, JE .
LANCET, 1992, 340 (8822) :741-745
[3]   Anti-CD20 antibody treatment in refractory Class IV lupus nephritis [J].
Carroll, Robert P. ;
Brown, Fiona ;
Kerr, Peter G. .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 (01) :291-293
[4]  
CHURG J, 1995, RENAL DIS CLASSIFICA, P151
[5]   Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts [J].
Diaz-Lagares, Candido ;
Croca, Sara ;
Sangle, Shirish ;
Vital, Edward M. ;
Catapano, Fausta ;
Martinez-Berriotxoa, Agustin ;
Garcia-Hernandez, Francisco ;
Callejas-Rubio, Jose-Luis ;
Rascon, Javier ;
D'Cruz, David ;
Jayne, David ;
Ruiz-Irastorza, Guillermo ;
Emery, Paul ;
Isenberg, David ;
Ramos-Casals, Manuel ;
Khamashta, Munther A. .
AUTOIMMUNITY REVIEWS, 2012, 11 (05) :357-364
[6]   Six refractory lupus patients treated with rituximab: A case series [J].
Gillis, Joann Zell ;
Dall'era, Maria ;
Gross, Andrew ;
Yazdany, Jinoos ;
Davis, John .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2007, 57 (03) :538-542
[7]   The reliability of the systemic Lupus International Collaborating Clinics American College of Rheumatology Damage Index in patients with Systemic Lupus Erythematosus [J].
Gladman, DD ;
Urowitz, MB ;
Goldsmith, CH ;
Fortin, P ;
Ginzler, E ;
Gordon, C ;
Hanly, JG ;
Isenberg, DA ;
Kalunian, K ;
Nived, O ;
Petri, M ;
SanchezGuerrero, J ;
Snaith, M ;
Sturfelt, G .
ARTHRITIS AND RHEUMATISM, 1997, 40 (05) :809-813
[8]   Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases [J].
Gottenberg, JE ;
Guillevin, L ;
Lambotte, O ;
Combe, B ;
Allanore, Y ;
Cantagrel, A ;
Larroche, C ;
Soubrier, M ;
Bouillet, L ;
Dougados, M ;
Fain, O ;
Farge, D ;
Kyndt, X ;
Lortholary, O ;
Masson, C ;
Moura, B ;
Remy, P ;
Thomas, T ;
Wendling, D ;
Anaya, JM ;
Sibilia, J ;
Mariette, X .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (06) :913-920
[9]   Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis [J].
Gunnarsson, Iva ;
Sundelin, Birgitta ;
Jonsdottir, Thorunn ;
Jacobson, Stefan H. ;
Henriksson, Elisabet Welin ;
van Vollenhoven, Ronald F. .
ARTHRITIS AND RHEUMATISM, 2007, 56 (04) :1263-1272
[10]  
HAY EM, 1993, Q J MED, V86, P447